drugset
drugset / Trial / NCT04881955

Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects

NCT04881955 ↗

Phase 1 Completed 8 enrolled Emalex Biosciences Inc. Covance · collab
NaSingle-groupOpen-labelBasic science

Summary

Phase 1, single-center (United Kingdom), open-label, nonrandomized, single-dose study in healthy adult male subjects to assess the absorption, metabolism, and excretion of \[14C\]-Ecopipam in Healthy Male Subjects.

Timeline

Start
2021-05-12
Primary completion
2021-09-07
Completion
2021-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecopipam Small molecule 200 mg Oral

Indications

No indication recorded.